1. Home
  2. AGIO vs RUN Comparison

AGIO vs RUN Comparison

Compare AGIO & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

N/A

Current Price

$32.48

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Logo Sunrun Inc.

RUN

Sunrun Inc.

N/A

Current Price

$7.65

Market Cap

2.1B

Sector

Miscellaneous

ML Signal

N/A

Company Overview

Basic Information
Metric
AGIO
RUN
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
AGIO
RUN
Price
$32.48
$7.65
Analyst Decision
Buy
Buy
Analyst Count
10
21
Target Price
★ $46.25
$15.87
AVG Volume (30 Days)
686.1K
★ 6.4M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 113.35
EPS
N/A
★ 1.04
Revenue
$43,011,000.00
★ $858,578,000.00
Revenue This Year
$237.78
$6.51
Revenue Next Year
$92.30
$1.55
P/E Ratio
★ N/A
$7.54
Revenue Growth
N/A
★ 12.97
52 Week Low
$22.24
$7.58
52 Week High
$46.00
$22.44

Technical Indicators

Market Signals
Indicator
AGIO
RUN
Relative Strength Index (RSI) 48.96 35.06
Support Level $32.17 N/A
Resistance Level $35.77 $8.95
Average True Range (ATR) 1.18 0.34
MACD -0.00 -0.04
Stochastic Oscillator 51.25 0.35

Price Performance

Historical Comparison
AGIO
RUN

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

Share on Social Networks: